Antetokounmpo added 12 rebounds and five assists while Milwaukee ended Clevelands four-game winning streak. click over here Jabari Parker had 18 points and Michael Beasley had 17 off the bench for the Bucks. LeBron James had 22 points for the Cavaliers, who fell to 13-3. Kyrie Irving added 20 points. Milwaukee led by 22 points in the fourth quarter and cruised past the defending champions, who benched their starters midway through the final period. The Bucksoutscored Cleveland by 14 points in the third quarter. Cleveland rode hot early shooting to a 14-point first quarter lead, but Milwaukee closed on a 10-0 run and trailed by only two at the end of the period. The hot hands of Antetokounmpo and Beasley sparked Milwaukee in the second quarter as the Bucksbuilt an advantage of eight points before leading 58-54 at the half.
For the original version including any supplementary images or video, visit http://fox6now.com/2016/11/29/giannis-antetokounmpo-ties-career-scoring-high-bucks-rout-cavs/
Its spokeswoman Allyson Funk said in a statement the trade group “appreciate[s] Congress’ continued interest in improving biomedical innovation and accelerating new treatments for patients.” Several nonprofit patient advocacy and research groups have opposed the bill, citing concerns about endangering patients with simplified drug and device approvals. Beyond the pharmaceutical industry, the bill’s supporters include universities, medical schools and groups no data representing them, as well as patient groups funded by drug and device companies, said Diana Zuckerman of the nonprofit National Center for Health Research, which has not lobbied the bill but has launched a campaign to convince Congress to “fix” it. “It really is a David and Goliath issue of where the money is,” Zuckerman said. AbbVie, the maker of Humira, a drug used to treat arthritis, ulcerative colitis and Crohn’s disease, reported $7.7 million in lobbying expenditures in disclosures listing the bill as an issue. The company’s total lobbying was $9.5 million this cycle. “It really is a David and Goliath issue of where the money is.” Hospitals and medical schools, which oppose rising drug costs , supported the bill because the NIH funding could propel grants to medical and research no data institutions, Zuckerman said. Johns Hopkins Medicine called enhanced biomedical research funding “long overdue.” Spokeswoman Jania Matthews said in look these up an email that the bill would also “provide new tools at the FDA to accelerate the approval of new therapies and medical devices.” The U.S. Chamber of Commerce generally supports the bill and reported $87.1 million in expenditures in disclosure reports that cited the Cures Act, with overall spending of $136.5 million through the second quarter of 2016. The U.S. Oil and Gas Association, with lobbying expenditures of $293,000, lists the Cures Act as a legislative issue. Funding for the bill would partly come from selling crude oil from the U.S.
For the original version including any supplementary images or video, visit http://www.nbcnews.com/health/health-news/cures-act-congress-heavily-influenced-lobbyists-n689531?cid=public-rss_20161130
You may also be interested to read
- medical interview strengths and weaknesses
- have a peek at this website
- this hyperlink